Literature DB >> 15711953

Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans.

Maurizio Zanetti1, Xavier Hernandez, Pierre Langlade-Demoyen.   

Abstract

Human telomerase reverse transcriptase, a ribonucleoprotein intimately connected with the process of cell immortalization, is overexpressed in the vast majority of cancer cells, irrespective of their histological origin. Telomerase is currently viewed as the first antigen with the characteristics of common tumor antigen in humans, and it constitutes a potentially valuable target for attempts to control tumors through CD8 T cell immunity. Telomerase is a self antigen, making it possible that self tolerance imposes severe restrictions on our ability to generate effective anti-tumor immune responses in humans. In this article we review current studies on the antigenic and immunogenic properties of the human telomerase reverse transcriptase, placing them in the context of self tolerance and the size of the available CD8 T cell repertoire restricted by the HLA A2 molecule.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711953     DOI: 10.1007/s00281-004-0197-8

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  84 in total

1.  Protocol #0207-545: a phase I/II, escalating dose, open-label evaluation of safety, feasibility, and tolerability of transgenic lymphocyte immunization (TLI) vaccine subjects with histologically proven prostate adenocarcinoma.

Authors:  Mauricio Zanetti
Journal:  Hum Gene Ther       Date:  2003-02-10       Impact factor: 5.695

2.  Absence of cancer-associated changes in human fibroblasts immortalized with telomerase.

Authors:  C P Morales; S E Holt; M Ouellette; K J Kaur; Y Yan; K S Wilson; M A White; W E Wright; J W Shay
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

3.  Telomere lengthening and telomerase activation during human B cell differentiation.

Authors:  N P Weng; L Granger; R J Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

4.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

5.  Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.

Authors:  M Ayyoub; M Migliaccio; P Guillaume; D Liénard; J C Cerottini; P Romero; F Lévy; D E Speiser; D Valmori
Journal:  Eur J Immunol       Date:  2001-09       Impact factor: 5.532

6.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.

Authors:  B Minev; J Hipp; H Firat; J D Schmidt; P Langlade-Demoyen; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.

Authors:  R H Vonderheide; K S Anderson; W C Hahn; M O Butler; J L Schultze; L M Nadler
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

8.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays.

Authors:  A Sette; J Sidney; M F del Guercio; S Southwood; J Ruppert; C Dahlberg; H M Grey; R T Kubo
Journal:  Mol Immunol       Date:  1994-08       Impact factor: 4.407

9.  Telomerase activity might persist in the human thymus throughout life.

Authors:  P Brousset; T al Saati; R C Zenou; G Delsol
Journal:  Mol Pathol       Date:  1998-06

10.  High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

Authors:  David-Alexandre Gross; Stéphanie Graff-Dubois; Paule Opolon; Sébastien Cornet; Pedro Alves; Annelise Bennaceur-Griscelli; Olivier Faure; Philippe Guillaume; Hüseyin Firat; Salem Chouaib; François A Lemonnier; Jean Davoust; Isabelle Miconnet; Robert H Vonderheide; Kostas Kosmatopoulos
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

View more
  2 in total

1.  Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response.

Authors:  Jessie Thalmensi; Elodie Pliquet; Christelle Liard; Marie Escande; Thomas Bestetti; Marion Julithe; Anna Kostrzak; Anne-Sophie Pailhes-Jimenez; Emanuèle Bourges; Maria Loustau; Julien Caumartin; Abderrahim Lachgar; Thierry Huet; Simon Wain-Hobson; Pierre Langlade-Demoyen
Journal:  Oncoimmunology       Date:  2015-11-05       Impact factor: 8.110

Review 2.  Telomerase immunity from bench to bedside: round one.

Authors:  Xochtil Cortez-Gonzalez; Maurizio Zanetti
Journal:  J Transl Med       Date:  2007-02-26       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.